Science Advisory Board review meeting took place on November 2
We have shared our latest R&D progress with our Science Advisory (SAB) review panel that took place at Machavert headquarters
news
Machavert closes A round financing of $4.5m
Machavert has closed their A Round of financing of ~$4.5m by raising $2.2 million in the second tranche of this
Machavert’s Annual General Meeting
Machavert’s Shareholders Annual General Meeting took place on June 27th in Prague, Czech Republic. Machavert’s management shared an exciting progress
Leading immuno-oncologist Norman Michael Greenberg joins Science Advisory Board of Machavert
We are very happy to welcome Dr. Norman Michael Greenberg to our Science Advisory Board (SAB). Norm will help us
We welcomed Prof. David Brautigan to his first meeting at our Science Advisory Board
David travelled from Charlottesville, Virginia to visit Machavert headquarters at Anschutz Medical Campus in Aurora, CO to meet our new
Shareholders General Meeting
Machavert’s Shareholders General Meeting took place on February 6 in Prague, Czech Republic. Machavert’s management presented an exciting progress update.
Dr. Neal Goodwin joins Machavert as Chief Science Officer
Machavert is excited to introduce Dr. Neal Goodwin, Ph.D. as the Chief Science Officer who will be responsible for all
Machavert welcomes Dennis R. Voelker as a member of Science Advisory Board
Dennis R. Voelker is Professor in the Department of Medicine and Director of Research, Pulmonary Division, National Jewish Health, Denver;
Meet Dan Theodorescu of the recently established Science Advisory Board
• Dan Theodorescu is the Director of the NCI designated Comprehensive Cancer Center at the University of Colorado where he